WHITE PAPER

Hematopoietic Colony Forming Cell (CFC) Assay

In this paper, we present data from internal ReachBio studies specific to neutropenia. The first section demonstrates the clinical relevance of CFC assays by correlating known clinical myelotoxicity outcomes of approved tyrosine kinase inhibitor (TKI) drugs with CFC data using the same drugs. This study also examines the use of bone marrow from multiple species, with comparisons to human samples. The second study looks at CFC assays using drug combinations. Because drug combinations can have additive or other synergistic effects on hematotoxicty, and because drugs are rarely administered to treatment-naïve patients, combination studies can provide useful preclinical information.